Experimental Novartis radiopharma drug shows promise in early study

Chronological Source Flow
Back

AI Fusion Summary

Novartis reports that its experimental radiopharmaceutical for prostate cancer showed encouraging results in an early study, with patients experiencing tumor shrinkage and manageable side effects, indicating potential for future clinical development in the United States.
Community Comments
Loading updates...
0